NDA 018893 · Hospira
Sodium Acetate
Sodium Acetate · Intravenous
Last checked: Nov 20, 2026Latest source record: Sep 2, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
May 4, 1983
Approved uses
1
Original approval plus efficacy supplements
Registered trials
232
60 Phase 3, 18 recruiting
FAERS reports
285
229 serious, 56 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
INDICATIONS AND USAGE Sodium Acetate Injection, USP (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 4, 1983 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- SODIUM ACETATE · SODIUM ACETATE 40MEQ/20ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- SODIUM ACETATE · SODIUM ACETATE 100MEQ/50ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- SODIUM ACETATE · SODIUM ACETATE 200MEQ/100ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Sodium Acetate" as an intervention, any sponsor and status, largest first.
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in SepsisPivotal-lookingCompleted
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT04102371 · 9,041 participants · Start Aug 25, 2020 · Primary completion Dec 1, 2025
Drug: Lactated Ringer; Normal Saline and 1 more · For: Shock; Septic
Sites: Davis, California; Los Angeles, California; San Francisco, California · 22 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT01222247 · 2,831 participants · Start Oct 2010 · Primary completion Mar 2015
Drug: Betamethasone; Placebo · For: Pregnancy; Respiratory Distress Syndrome; Pregnancy Outcomes and 1 more
Sites: Birmingham, Alabama; Stanford, California; Denver, Colorado · 17 sites in all
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
Phoenix Molecular ImagingAcademic, hospital or other
NCT01304485 · 2,000 participants · Start Apr 2011 · Primary completion Jan 2019
Drug: Sodium Acetate C11 · For: Prostate Cancer
Sites: Phoenix, Arizona
- Albumin in Cardiac SurgeryPivotal-lookingCompleted
Helsinki University Central HospitalAcademic, hospital or other
NCT02560519 · 1,386 participants · Start Mar 21, 2017 · Primary completion Apr 13, 2020
Drug: Albumin solution; Ringers acetate solution · For: C.Surgical Procedure; Cardiac
Sites: Helsinki, Finland
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04492475 · 969 participants · Start Aug 5, 2020 · Primary completion Dec 21, 2020
Drug: Interferon beta-1a; Remdesivir · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 64 sites in all
- Benefits of GIK in Cardiac Surgery PatientsPivotal-lookingStatus unknown
Xijing HospitalAcademic, hospital or other
NCT01516138 · 930 participants · Start Feb 2012 · Primary completion Mar 2013
Drug: GIK; Control · For: Cardiac Surgery; Cardiopulmonary Bypass
Sites: Xi'an, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use29
- pyrexia23
- nausea18
- diarrhoea17
- dyspnoea16
- pneumonia16
- vomiting16
- death15
- anaemia14
- condition aggravated13
- drug intolerance13
- fatigue13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 12 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 14 |
| 2014 | 7 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 14 |
| 2018 | 23 |
| 2019 | 26 |
| 2020 | 11 |
| 2021 | 25 |
| 2022 | 20 |
| 2023 | 14 |
| 2024 | 33 |
| 2025 | 15 |
| 2026 | 19 |
Recalls
1 FDA enforcement reports for this application.
Feb 26, 2013 · Class II · Terminated
Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73).
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05).
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06).
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26).
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25).
Current · updated Nov 9, 2026
Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sodium Acetate (Sodium Acetate)
2024 spending
$44K
Beneficiaries
42
501 claims
Per beneficiary
$1,059
$0.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,881 |
| 2021 | $14,741 |
| 2022 | $24,938 |
| 2023 | $51,001 |
| 2024 | $44,487 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Examination of the antiglycemic properties of vinegar in healthy adults.
Johnston CS, Steplewska I, Long CA, et al. · Ann Nutr Metab 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Short-chain fatty acid topical treatment in distal ulcerative colitis.
Vernia P, Marcheggiano A, Caprilli R, et al. · Aliment Pharmacol Ther 1995 · Clinical Trial, Randomized Controlled Trial
- Dietary herb extract rikkunshi-to ameliorates gastroparesis in Parkinson's disease: a pilot study.
Doi H, Sakakibara R, Sato M, et al. · Eur Neurol 2014 · Clinical Trial
- Gastric Emptying of Elemental Liquid Diets Versus Semisolid Diets in Bedridden Gastrostomy-fed Patients.
Horiuchi A, Sakai R, Tamaki M, et al. · J Clin Gastroenterol 2019 · Randomized Controlled Trial
- Effect of rectal infusion of short chain fatty acids in human subjects.
Wolever TM, Brighenti F, Royall D, et al. · Am J Gastroenterol 1989 · Clinical Trial, Randomized Controlled Trial
- Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct.
Postiglione A, Soricelli A, Cicerano U, et al. · Pharmacol Res 1991 · Clinical Trial, Controlled Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.